Social media 'high priority' for FDA 2012, despite lack of 2012 guidance
This article was originally published in Scrip
The list of new and revised guidelines that the US Food and Drug Administration is planning to publish in 2012 makes no mention of its long-awaited guidance on promotion of prescription drugs using social media tools. However, the agency has confirmed to Scrip's sister publication, Scrip Regulatory Affairs, that it has not put this topic on the backburner and that "policy and guidance development for promotion of FDA-regulated medical products using the Internet and social media tools are among our highest priorities".
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.